ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. The company’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat Medulloblastoma, a pediatric malignant brain tumor; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc., as well as Parexel to provide clinical research services for the development of JETREA. The company was founded in 1991 and is headquartered in Leuven, Belgium.
thrombogenics nv (THR:EN Brussels)
Gaston Geenslaan 1
Phone: 32 1 675 13 10
Fax: 32 1 675 13 11www.thrombogenics.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for THR.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact THROMBOGENICS NV, please visit www.thrombogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.